Parkinson’s Disease

Parkinson’s Disease / 2019 / Article

Review Article | Open Access

Volume 2019 |Article ID 6280896 | 9 pages | https://doi.org/10.1155/2019/6280896

Improvement of Subthalamic Nucleus Deep Brain Stimulation in Sleeping Symptoms in Parkinson’s Disease: A Meta-Analysis

Academic Editor: Giuseppina Martella
Received16 Jul 2019
Revised30 Aug 2019
Accepted09 Sep 2019
Published08 Oct 2019

Abstract

Introduction. The aim of this meta-analysis was to evaluate the effects of STN DBS on sleep quality and restless leg symptoms in individuals with PD. Methods. We searched the PubMed, Web of Science, EMBASE, CNKI, and WANFANG databases published between 1990 and 2019. The articles included were those that contained both pre- and postsurgery data acquired using International RLS Study Group criteria and the Pittsburgh sleep quality index (PSQI) questionnaire with patients’ follow-up of at least three months. All studies that met the quality requirements were included in a meta-analysis performed using STATA 12.0 software. Results. Of 73 articles identified, 7 studies comprising 82 patients were qualified for the current meta-analysis. After adjusting for heterogeneity in study effect sizes, the random effects meta-analysis indicated that STN DBS improved sleep quality and restless leg symptoms significantly (SMD = −1.111, 95% CI: −1.918∼−0.304, ). Subgroup analysis showed that different sleep scoring criteria had different effects on the condition of sleeping after surgery. Conclusions. STN DBS is a powerful method in the management of sleep quality and restless leg symptoms in PD patients, but its long-term effects with larger populations must be thoroughly assessed.

1. Introduction

Parkinson’s disease (PD), as a primary reason of morbidity and mortality worldwide, is a debilitating neurodegenerative condition characterized by motor and nonmotor symptoms among middle-aged and elderly individuals. As for treatment methods, currently, antiparkinsonian medication and surgical interventions have become mainstream [1, 2]. Generally, antiparkinsonian drugs, which are currently the first-line therapy for PD, are mostly used in patients during the early stage of the disease [3]. On the other hand, surgery using deep brain stimulation (DBS) is done during mid-stage to late-stage of the disease in patients with decreased sensitivity to available medicines or in patients with drug-induced complications [4].

Deep brain stimulation, which involves the application of electrical stimuli in specific nuclei, was clinically used in the late 1990s for the treatment of PD, and this technique has been widely and increasingly accepted during last 20 years. Currently, STN DBS significantly improves patients’ primary motor symptoms as well as the quality of life, reducing their need for medications [5, 6]. The influence of STN DBS on nonmotor symptoms (NMS) of PD has received only a smaller amount of attention, even though recent records indicate that NMS occur in up to 100% of PD patients [7]. Nonmotor symptoms which include sleep disorders, cognitive deficiency, and autonomic deficiency are common and they all have a noteworthy effect on disability and subsequently quality of life [8]. Hence, it is imperative to frequently evaluate the development or deterioration of nonmotor symptoms in DBS patients.

Sleep disturbances are an integral aspect of the NMS of PD, which are common in PD patients, becoming increasingly more frequent and severe during the advanced stage of the disease [9, 10]. Lees et al. [11] conducted a national survey and found that more than 95% of advanced PD patients suffer from sleep disorders. Restless leg syndrome (RLS) is a sleep-related movement disorder characterized by the urge to move one’s legs frequently accompanied by uncomfortable and unpleasant sensations during the period of rest or inactivity that interferes with the sleep of sufferers [12]. RLS can affect up to 24% of the adult population and may be increased in patients with Parkinson’s disease (PD) [13]. Its pathophysiology is not known; however, it is supposed to be associated with diminished central dopaminergic transmission [14]. Reports are limited on the effect of PD surgery on RLS symptoms, and existing publications demonstrate conflicting results [1518]. In this meta-analysis, we synthesized the results of published research on patient outcomes following bilateral DBS of the STN on sleep quality and restless leg symptoms and would be of great clinical value when considering patients and DBS target selection.

2. Materials and Methods

2.1. Literature Search

We selected the studies which investigated sleep quality and restless leg symptoms of patients with PD before and after bilateral DBS. An initial literature search was done by means of PubMed, Web of Science, EMBASE, CNKI, and WANFANG databases for the years 1990 to 2019. The search terms were (“bilateral deep brain stimulation” OR “bilateral stimulation”) OR (“bilateral stimulation” AND “subthalamic nucleus”) AND (“Parkinson disease” OR “Parkinson’s disease”) AND (“sleep” OR “restless legs syndrome”). In addition, we searched the references of the recognized studies to find other satisfactory studies. This task was completed by two reviewers independently. When disagreements arose, a third reviewer was consulted.

2.2. Inclusion and Exclusion Criteria

The inclusion criteria were the following: (1) patients with idiopathic PD were treated with bilateral STN DBS, (2) the patients were followed up for at least 3 months, (3) presurgery and postsurgery data were obtained through International Restless Legs Syndrome Study Group (IRLSSG) criteria or PSQI questionnaire, respectively (RLS diagnosis was made according to established criteria including 4 essential features of RLS [19]. PSQI contains seven components with scores ranging from 0 to 21, and higher scores indicate worse sleep quality [20]), and (4) data were analyzed in the form of mean and standard deviation. The exclusion criteria were as follows: (1) preclinical studies reviews, meta-analysis, book chapters, letters to the editor, or case reports with no innovative data, (2) duplicated reports with identical data, (3) data from nonhuman species, and (4) insufficient original data.

2.3. Quality Assessment

Two reviewers evaluated the quality of the studies by means of the Methodological Index for Nonrandomized Studies (MINORS), which involves eight items. Each item was scored from 0 to 2: 0 representing that it was not reported in the article, 1 representing that it was reported but inadequately, and 2 representing that it was reported adequately [21].

2.4. Extraction

Two investigators reviewed the publications independently and extracted the applicable data from each qualified study, whereas objections were resolved by consulting a third reviewer. The below mentioned details were extracted: name of the first author, year of publication, sample size, duration of disease, time of following up, DBS programming, and the relevant pre- and posttreatment IRLS score and PSQI score concerning the STN DBS.

2.5. Statistical Analysis

STATA statistics software (version 12.0, USA) was used to analyze accessible data. Since two scales were used in our study, standardized mean difference (SMD), that is, Cohen’s d, was used to estimate the size of the combined effect, with a confidence interval of 95%. SMD, as a standard statistic, was used to evaluate the comparisons of presurgery and postsurgery change. This value reflects an intervention-induced change of the outcome on an average and is used as a summary statistic in meta-analysis if the studies were measured in different ways. As for the heterogeneity of all the studies, Q-test and I2-statistics were used to evaluate the degree of it. An I2 > 50% or designated significant heterogeneity, then a random-effects model would be used for meta-analysis [22]. Sensitivity analysis was performed by excluding each study and reanalyzing the remaining studies. Begg’s test that measures funnel plot asymmetry was used to evaluate publication biases. A value of <0.05 for Begg’s test was considered statistically significant [23].

3. Results

3.1. Characteristics of Eligible Studies

We recognized 73 published studies, from which we omitted 12 because of the duplication. We further excluded 41 studies after evaluating titles and abstracts as they did not meet the inclusion criteria. After reading the full text of the remaining 20 articles, we omitted 13 studies due to lack of control groups. Finally, we had 7 eligible studies which fulfilled the inclusion criteria. Figure 1 displays the flowchart of the screening method. All the included studies were follow-up type studies, with following up time ranging from 3 months to 12 months. The sample size was 82, and 45 patients were evaluated by means of the International RLS Study Group criteria, whereas 37 patients were evaluated by means of PSQI questionnaire. The PD patients involved underwent bilateral DBS before and after surgery. The main areas studied are described in Table 1. Quality assessment results from 7 included articles evaluated using MINORS analyses are presented in Table 2.


AuthorYearNAgeDisease durationDBS programmingScaleFollow-upPreoperative scorePreoperative LEPostoperative scorePostoperative LE

Klepitskaya et al. [24]20182258.3 ± 7.410.2 ± 4.9STN-DBSIRLSSG criteria6 months19.59 ± 6.951203.2 ± 657.514.53 ± 12.27370.8 ± 69.2
Kedia et al. [18]2004116114.2STN-DBSIRLSSG criteria6 months15 ± 5.91169.4 ± 702.74.3 ± 3.1294.0 ± 384.3
Chahine et al. [16]2011662 ± 8.813.1 ± 8STN-DBSIRLSSG criteria6 months23.0 ± 5.81193.8 ± 600.713.8 ± 8.6599.6 ± 369.7
Driver-Dunckley et al. [17]2006665.1 ± 10.313.7 ± 3.1STN-DBSIRLSSG criteria3 months24.8 ± 8.31591.5 ± 536.34 ± 5.8699.2 ± 509.4
Qian et al. [25]20131659.5 ± 8.58.9 ± 2.9STN-DBSPSQI24 months12 ± 3756.5 ± 255.212 ± 4420.8 ± 300.1
Chen et al. [26]20111059 ± 109 ± 3STN-DBSPSQI12 months11 ± 3711 ± 25312 ± 4361 ± 206
Iranzo et al. [27]20021163.6 ± 7.817.3 ± 9.1STN-DBSPSQI6 months14.8 ± 4.55.4 ± 4.6

IRLSSG criteria: International restless leg syndrome study group (IRLSSG) criteria; PSQI: the Pittsburgh sleep quality index (PSQI) questionnaire; and LE: levodopa equivalents.

StudyABCDEFGHTotal

Klepitskaya et al. [24]2022022010
Kedia et al. [18]2022022111
Chahine et al. [16]2022022111
Driver-Dunckley et al. [17]2222022012
Qian et al. [25]2022022010
Chen et al. [26]2022022010
Iranzo et al. [27]2222022012

A: a clearly stated aim; B: inclusion of consecutive patients; C: prospective collection of data; D: endpoints appropriate to the aim of the study; E: unbiased assessment of the study endpoint; F: follow-up period appropriate to the aim of the study; G: loss to follow-up less than 5%; H: prospective calculation of the sample size.
3.2. Quantitative Synthesis

Meta-analysis results of changes of RLS and sleeping after operation are displayed in Figure 2. The heterogeneity between the included studies showed that I2 = 80.4%; therefore, the random effects model was used to count the combined SMD. Based on the comparison of preoperative and postoperative change, we found that there was a significant change in the score among the presurgery stage and the postsurgery stage (SMD = −1.111, 95% CI: −1.918∼−0.304, ) (Figure 2).

Subgroup analysis was then conducted according to different scoring criteria. The results showed that the sleep quality of PD patients could be improved after STN DBS using IRLS scoring criteria (SMD = −1.598, 95% CI: −2.710∼−0.485, ), whereas no significant difference was observed in the PSQI score between the presurgery stage and the postsurgery stage (SMD = −0.551, 95% CI: −1.835∼0.733, ) (Figure 3).

3.3. Sensitivity Analysis and Publication Bias

In the sensitivity analysis, each study was omitted by turns to show the influence of every article contributing to this meta-analysis. No significant alterations were found in the pooled SMD, which showed a high level of stability of this meta-analysis (Figure 4). Begg’s test was used to evaluate publication bias, and the funnel plot was approximately symmetric, indicating that there was no publication bias () (Figure 5).

4. Discussion

Deep brain stimulation (DBS) has become an attractive alternative for the treatment of neurodegenerative diseases. STN DBS has been well established over the past 20 years for the symptomatic treatment of motor symptoms and complications in advanced PD. It provides more constant and predictable benefits than pharmacological therapy. Numerous studies have documented that the majority of patients who undergo STN DBS achieve amelioration of motor symptoms and quality of life. Nonmotor symptoms (NMS) are nowadays recognized as an integral part of the clinical characteristics of PD, both at the early stages and throughout the whole course of the disease, and even at the very beginning of the disease, before any of the classical motor symptoms develop [28]. Many published meta-analyses have showed evidence for an adverse effect on cognition, depression, and apathy [2931]. The present article is, to our knowledge, the first meta-analysis focusing on the effects of DBS on sleep quality and restless leg symptoms.

In particular, sleep disturbances in addition to neuropsychiatric symptoms (depression, cognitive dysfunctions, and psychosis) affect numerous PD patients. Sleep disruption is one of the most common nonmotor symptoms of PD and problematic in PD with estimates that as many as 90% of PD patients suffer from sleep problem [32]. There is substantial dissimilarity in the results of preceding studies using PSQI questionnaire on post-DBS sleep changes [2527]. Moreover, previous studies have reported contradictory outcomes regarding the effects of STN DBS on RLS in PD. Kedia et al. [18] indicated that 11 PD patients out of 195 (5.6%) had the occurrence of problematic RLS after DBS STN, which is similar with Marques research that six patients out of 31 (19%) described postoperative onset of restless leg syndrome [33]. However, numerous studies have described improvement in RLS symptoms after STN DBS in patients with PD [18, 24, 34]. Klepitskaya et al. [24] established a significant improvement of the IRLS score and severity in 22 patients with PD and moderate-to-severe RLS after STN DBS. These improvements lasted for up to 2 years after surgery despite a significant reduction in dopaminergic therapy (34.5%–69.2%).

The present meta-analysis included 7 studies containing 82 PD patients comparing the differences in sleeping changes between presurgery and postsurgery patients. Through strict methodological and statistical analysis, our data suggested that there was a statistical significant difference in the scores between the presurgery stage and the postsurgery stage (SMD = −1.111, 95% CI: −1.981∼−0.304, ), which means that bilateral STN DBS did seem to improve the PD patients’ sleeping condition. However, the subgroup analysis showed that different scoring criteria for sleeping had an impact on the condition of sleeping quality after surgery.

It is well recognized that several factors lead to sleep dysfunction in PD. Significantly, it has been established that degeneration of dopaminergic and nondopaminergic neurons underlying PD might have a part in PD-related sleep dysfunction, and if night-time awakenings at the end of a sleep cycle were followed by dystonia, prolonged periods of wakefulness will occur [35]. The sleep improvement induced by STN DBS has been explained by alleviation of nocturnal motor symptoms and reduction in doses of antiparkinsonian medications. In addition, it is possible that stimulation of the STN has effects on sleep regulatory centers by increasing slow-wave sleep as well as REM sleep but not altering the relative proportion of each sleep stage [36]. Enhancing the elimination of the possibly neurotoxic waste products that mount up in the awake central nervous system might also advance sleep functions [37].

In idiopathic RLS, low-dose dopaminergic therapy is effective, and chronic dopaminergic treatment can induce exacerbation and extension of RLS symptoms, called “augmentation.” This study showed that successful STN DBS was accompanied by a decrease of dopaminergic medication, which suggests that reduction in doses of antiparkinsonian medications may be an explanation for the improvement of RLS. Dopamine neurons are involved in the processes such as voluntary movement (Nigrostriatal system), cognitive/emotive functions (mesocorticolimbic system), and prolactin secretion (tuberoinfundibular system) [38, 39]. Dopaminergic pathology has been suggested to be related to the pathophysiological mechanism of RLS. Postoperative improvement of RLS is thought to be related to variations in basal ganglion neuron firing with downstream effects on the thalamus, which decreases the downstream disinhibition at the spinal level, thus alleviating abnormal sensations and motor restlessness [40]. Recent literature on the pathophysiology of RLS has implicated central dopaminergic dysfunction in several regions including the substantia nigra, striatum, putamen, and downstream disinhibition of the sensory dorsal horn and the intermediolateral nucleus of the spinal cord. DBS is a powerful treatment of dopamine-responsive symptoms of PD; therefore, it is reasonable to expect that DBS treatment can indirectly alleviate symptoms of other dopamine-responsive conditions, such as RLS.

This study provides evidence that STN DBS significantly improves sleep quality and restless leg symptoms at more than 3 months postoperatively compared to the preoperative baseline. There are several limitations of this article. First, the sample size of STN DBS was small, so additional studies are required to completely clarify the sleeping quality related to STN-DBS. Second, only the short-term effectiveness of DBS in treating PD was evaluated, thus, if our conclusion was suitable for long-term treatment was not clear. Significant heterogeneity was observed in this analysis. A potential explanation may be that relevant variables (e.g., sleep scoring criteria, published year, duration of PD, age, ethnicity, follow-up, etc.) in each study were different.

5. Conclusion

In conclusion, STN DBS is a powerful method in the management of sleep quality and restless leg symptoms in PD patients. Further improvements, through basic research and methodological innovations, should make it applicable to long-term treatment of the disease. Considering the limitations stated above, further larger samples and multicenter cooperative studies in different populations should be carried out, and the precise intervention protocols for PD patients with different disease stages should be taken in future findings.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

The authors would like to acknowledge the investigators for their helpful comments regarding this paper. This work was supported by grants from Natural Science Foundation of China (81571225).

References

  1. A. Ascherio and M. A. Schwarzschild, “The epidemiology of parkinson’s disease: risk factors and prevention,” The Lancet Neurology, vol. 15, no. 12, pp. 1257–1272, 2016. View at: Publisher Site | Google Scholar
  2. J. Jankovic and W. Poewe, “Therapies in parkinson’s disease,” Current Opinion in Neurology, vol. 25, no. 4, pp. 433–447, 2012. View at: Publisher Site | Google Scholar
  3. R. Pahwa and K. E. Lyons, “Treatment of early parkinson’s disease,” Current Opinion in Neurology, vol. 27, no. 4, pp. 442–449, 2014. View at: Publisher Site | Google Scholar
  4. J. C. Giugni and M. S. Okun, “Treatment of advanced parkinson’s disease,” Current Opinion in Neurology, vol. 27, no. 4, pp. 450–460, 2014. View at: Publisher Site | Google Scholar
  5. F. Jia, A. Wagle Shukla, W. Hu et al., “Deep brain stimulation at variable frequency to improve motor outcomes in parkinson’s disease,” Movement Disorders Clinical Practice, vol. 5, no. 5, pp. 538–541, 2018. View at: Publisher Site | Google Scholar
  6. G. A. Shahidi, M. Rohani, M. Parvaresh et al., “Outcome of subthalamic nucleus deep brain stimulation on long-term motor function of patients with advanced parkinson disease,” Iranian Journal of Neurology, vol. 16, no. 3, pp. 107–111, 2017. View at: Google Scholar
  7. T. M. Zhang, S. Y. Yu, P. Guo et al., “Nonmotor symptoms in patients with parkinson disease: a cross-sectional observational study,” Medicine (Baltimore), vol. 95, no. 50, Article ID e5400, 2016. View at: Publisher Site | Google Scholar
  8. C. H. Adler, “Nonmotor complications in parkinson’s disease,” Movement Disorders, vol. 20, no. S11, pp. S23–S29, 2005. View at: Publisher Site | Google Scholar
  9. N. J. Diederich and D. J. McIntyre, “Sleep disorders in Parkinson's disease: many causes, few therapeutic options,” Journal of the Neurological Sciences, vol. 314, no. 1-2, pp. 12–19, 2012. View at: Publisher Site | Google Scholar
  10. O. Riedel, J. Klotsche, A. Spottke et al., “Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with parkinson’s disease,” Journal of Neurology, vol. 257, no. 7, pp. 1073–1082, 2010. View at: Publisher Site | Google Scholar
  11. A. J. Lees, N. A. Blackburn, and V. L. Campbell, “The nighttime problems of parkinson’s disease,” Clinical Neuropharmacology, vol. 11, no. 6, pp. 512–519, 1988. View at: Publisher Site | Google Scholar
  12. M. M. Ohayon, R. O’Hara, and M. V. Vitiello, “Epidemiology of restless legs syndrome: a synthesis of the literature,” Sleep Medicine Reviews, vol. 16, no. 4, pp. 283–295, 2012. View at: Publisher Site | Google Scholar
  13. D. A. Nichols, R. P. Allen, J. H. Grauke et al., “Restless legs syndrome symptoms in primary care: a prevalence study,” Archives of Internal Medicine, vol. 163, no. 19, pp. 2323–2329, 2003. View at: Publisher Site | Google Scholar
  14. C. Trenkwalder and W. Paulus, “Why do restless legs occur at rest?—pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2),” Clinical Neurophysiology, vol. 115, no. 9, pp. 1975–1988, 2004. View at: Publisher Site | Google Scholar
  15. J. Dulski, M. Schinwelski, A. Konkel et al., “The impact of subthalamic deep brain stimulation on polysomnographic sleep pattern in patients with parkinson’s disease—preliminary report,” Neurologia i Neurochirurgia Polska, vol. 52, no. 4, pp. 514–518, 2018. View at: Publisher Site | Google Scholar
  16. L. M. Chahine, A. Ahmed, and Z. Sun, “Effects of STN DBS for parkinson’s disease on restless legs syndrome and other sleep-related measures,” Parkinsonism & Related Disorders, vol. 17, no. 3, pp. 208–211, 2011. View at: Publisher Site | Google Scholar
  17. E. Driver-Dunckley, V. G. Evidente, C. H. Adler et al., “Restless legs syndrome in parkinson’s disease patients may improve with subthalamic stimulation,” Movement Disorders, vol. 21, no. 8, pp. 1287–1289, 2006. View at: Publisher Site | Google Scholar
  18. S. Kedia, E. Moro, M. Tagliati, A. E. Lang, and R. Kumar, “Emergence of restless legs syndrome during subthalamic stimulation for parkinson disease,” Neurology, vol. 63, no. 12, pp. 2410–2412, 2004. View at: Publisher Site | Google Scholar
  19. R. P. Allen, D. Picchietti, W. A. Hening et al., “Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health,” Sleep Medicine, vol. 4, no. 2, pp. 101–119, 2003. View at: Publisher Site | Google Scholar
  20. D. J. Buysse, C. F. Reynolds, T. H. Monk, S. R. Berman, and D. J. Kupfer, “The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research,” Psychiatry Research, vol. 28, no. 2, pp. 193–213, 1989. View at: Publisher Site | Google Scholar
  21. K. Slim, E. Nini, D. Forestier, F. Kwiatkowski, Y. Panis, and J. Chipponi, “Methodological index for non-randomized studies (minors): development and validation of a new instrument,” ANZ Journal of Surgery, vol. 73, no. 9, pp. 712–716, 2003. View at: Publisher Site | Google Scholar
  22. J. P. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, 2003. View at: Publisher Site | Google Scholar
  23. J. L. Peters, A. J. Sutton, D. R. Jones, K. R. Abrams, and L. Rushton, “Comparison of two methods to detect publication bias in meta-analysis,” JAMA, vol. 295, no. 6, pp. 676–680, 2006. View at: Publisher Site | Google Scholar
  24. O. Klepitskaya, Y. Liu, S. Sharma, S. H. Sillau, J. Tsai, and A. S. Walters, “Deep brain stimulation improves restless legs syndrome in patients with parkinson disease,” Neurology, vol. 91, no. 11, pp. e1013–e1021, 2018. View at: Publisher Site | Google Scholar
  25. H. Qian, J. L. Liu, X. L. Fu et al., “Effects of bilateral subthalamic nucleus deep brain stimulation on motor and nonmotor symptoms in patients with moderate and advanced parkinson’s disease-a two-year follow-up study,” Chinese Journal of Nervous and Mental Diseases, vol. 39, no. 5, pp. 284–290, 2013. View at: Google Scholar
  26. J. Chen, J. L. Liu, X. Chen et al., “Significant improvement of motor symptoms by deep brain stimulation of bilateral subthalamic nucleus in patients with moderate or advanced parkinson’s disease,” Zhonghua Yi Xue Za Zhi, vol. 91, no. 5, pp. 291–295, 2011. View at: Google Scholar
  27. A. Iranzo, F. Valldeoriola, J. Santamaria, E. Tolosa, and J. Rumià, “Sleep symptoms and polysomnographic architecture in advanced parkinson’s disease after chronic bilateral subthalamic stimulation,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 72, no. 5, pp. 661–664, 2002. View at: Publisher Site | Google Scholar
  28. A. Sauerbier and K. Ray Chaudhuri, “Non-motor symptoms: the core of multi-morbid parkinson’s disease,” British Journal of Hospital Medicine, vol. 75, no. 1, pp. 18–24, 2014. View at: Publisher Site | Google Scholar
  29. M. I. Couto, A. Monteiro, A. Oliveira, N. Lunet, and J. Massano, “Depression and anxiety following deep brain stimulation in parkinson’s disease: systematic review and meta-analysis,” Acta Médica Portuguesa, vol. 27, no. 3, pp. 372–382, 2014. View at: Publisher Site | Google Scholar
  30. J. W. Wang, Y. Q. Zhang, X. H. Zhang, Y.-P. Wang, J.-P. Li, and Y.-J. Li, “Cognitive and psychiatric effects of STN versus GPi deep brain stimulation in parkinson’s disease: a meta-analysis of randomized controlled trials,” PLoS One, vol. 11, no. 6, Article ID e0156721, 2016. View at: Publisher Site | Google Scholar
  31. Y. Wang, Y. Li, X. Zhang, and X. Anmu, “Apathy following bilateral deep brain stimulation of subthalamic nucleus in parkinson’s disease: a meta-analysis,” Parkinson’s Disease, vol. 2018, Article ID 9756468, 7 pages, 2018. View at: Publisher Site | Google Scholar
  32. A. Videnovic, “Management of sleep disorders in parkinson’s disease and multiple system atrophy,” Movement Disorders, vol. 32, no. 5, pp. 659–668, 2017. View at: Publisher Site | Google Scholar
  33. A. Marques, M. L. Fantini, D. Morand et al., “Emergence of restless legs syndrome after subthalamic stimulation in parkinson’s disease: a dopaminergic overstimulation?” Sleep Medicine, vol. 16, no. 5, pp. 583–588, 2015. View at: Publisher Site | Google Scholar
  34. U. Hidding, A. Gulberti, C. Pflug et al., “Modulation of specific components of sleep disturbances by simultaneous subthalamic and nigral stimulation in parkinson’s disease,” Parkinsonism & Related Disorders, vol. 62, pp. 141–147, 2019. View at: Publisher Site | Google Scholar
  35. C. W. Olanow, M. B. Stern, and K. Sethi, “The scientific and clinical basis for the treatment of parkinson disease (2009),” Neurology, vol. 72, no. 21, pp. S1–S136, 2009. View at: Publisher Site | Google Scholar
  36. N. Nishida, T. Murakami, K. Kadoh et al., “Subthalamic nucleus deep brain stimulation restores normal rapid eye movement sleep in parkinson’s disease,” Movement Disorders, vol. 26, no. 13, pp. 2418–2422, 2011. View at: Publisher Site | Google Scholar
  37. L. Xie, H. Kang, Q. Xu et al., “Sleep drives metabolite clearance from the adult brain,” Science, vol. 342, no. 6156, pp. 373–377, 2013. View at: Publisher Site | Google Scholar
  38. L. Ferini-Strambi, G. Carli, F. Casoni, and A. Galbiati, “Restless legs syndrome and Parkinson disease: a causal relationship between the two disorders?” Frontiers in Neurology, vol. 9, p. 551, 2018. View at: Publisher Site | Google Scholar
  39. A. Herrera-Solis, W. Herrera-Morales, L. Nunez-Jaramillo, and O. Arias-Carrion, “Dopaminergic modulation of sleep-wake states,” CNS & Neurological Disorders-Drug Targets, vol. 16, no. 4, pp. 380–386, 2017. View at: Publisher Site | Google Scholar
  40. Y. Dauvilliers, M. Tafti, and H. P. Landolt, “Catechol-O-methyltransferase, dopamine, and sleep-wake regulation,” Sleep Medicine Reviews, vol. 22, pp. 47–53, 2015. View at: Publisher Site | Google Scholar

Copyright © 2019 Xue Zhang and Anmu Xie. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

584 Views | 409 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.